Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.22 USD

29.22
24,234,574

-0.05 (-0.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat

Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.

    Sweta Killa headshot

    Pharma ETFs Down Post Q3 Earnings

    The string of earnings beat failed to boost pharma ETFs as they saw rough trading over the past one month.

      Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus

      Increased operating expenses mar Aerie's (AERI) Q3 performance.

        Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND

        The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if some small biotechs, due to report on Nov 9, follow suit.

          What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?

          Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business.

            Arpita Dutt headshot

            Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah

            It was all about earnings last week with companies like Pfizer (PFE), Teva and Allergan reporting third quarter results.

              Swarup Gupta headshot

              Dow 30 Stock Roundup: Chevron, Exxon, Apple Earnings Impress

              The Dow continued to notch up gains during a week marked by key legislative developments.

                Key Predictions for Q3 Earnings Reports of MYL, HZNP & KERX

                The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if generic maker Mylan and other small companies follow suit.

                  Momenta's (MNTA) Biosimilar Study Fails, Q3 Loss Narrows

                  Momenta Pharmaceuticals (MNTA) study to evaluate a biosimilar version of Orencia failed which overshadowed the third-quarter results.

                    AmerisourceBergen (ABC) Beats Q4 Earnings, Issues FY18 View

                    Solid growth in the Pharmaceutical Distribution Services segment drove AmerisourceBergen's (ABC) top line in the fourth quarter.

                      Company News For Nov 1, 2017

                      Companies in the news are: PFE, UA,AET, ACOR

                        Pfizer (PFE) Beats on Q3 Earnings, Raises 2017 EPS View

                        Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised its adjusted earnings guidance while tightening revenue expectations for 2017.

                          Stocks To Watch Out For This Halloween

                          Stocks To Watch Out For This Halloween

                            Mark Vickery headshot

                            Will Markets Stay Spooked This Halloween?

                            While econ data looks favorable, ahead of the opening bell we also see plenty of strength in Q3 performance.

                              Pfizer (PFE) Tops Q3 Earnings Estimates, Sales In Line

                              Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised adjusted earnings guidance while tightening the revenue expectations for 2017.

                                Is Aerie (AERI) Poised for a Beat This Earnings Season?

                                Aerie Pharmaceuticals (AERI) is looking solid on strong prospects of its lead candidate, Rhopressa. We expect investors to focus on further pipeline updates on the third-quarter call.

                                  What's in the Cards for PFE, INCY and ACOR in Q3 Earnings?

                                  The third-quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players like Pfizer, Incyte and Acorda follow suit.

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: Lilly Tops on All Fronts, Mixed Results from Bristol-Myers

                                    It was all about earnings this week with companies like Eli Lilly (LLY), Bristol-Myers Squibb and Novartis reporting third quarter results.

                                      The Zacks Analyst Blog Highlights: Merck, Pfizer, Aetna and Electronic Arts

                                      The Zacks Analyst Blog Highlights: Merck, Pfizer, Aetna and Electronic Arts

                                        Glaxo (GSK) Q3 Earnings Beat, Revenues In Line, Shares Down

                                        Glaxo's (GSK) Q3 earnings top estimates while revenues match the same. However, the bottom was flat at constant exchange rates (CER).

                                          Swarup Gupta headshot

                                          Merck vs. Pfizer: Which is Better Ahead of Q3 Earnings?

                                          With Merck and Pfizer scheduled to report on Oct 27 and Oct 31, respectively this may be a good time to consider which of these is a better stock.

                                            Is a Beat Likely for Pfizer (PFE) This Earnings Season?

                                            While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q3, genericization of key drugs, pricing pressure and rising competition will hurt sales.

                                              Corning (GLW) Beats Q3 Earnings on High Gorilla Glass Demand

                                              Corning's (GLW) third-quarter results benefited from the revenue upside driven by strong sales of Gorilla Glass and fiber products.

                                                Can AbbVie (ABBV) Spring a Surprise this Earnings Season?

                                                Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q3.

                                                  Sweta Killa headshot

                                                  Healthcare ETFs Set to Soar as Q3 Earnings Unfold

                                                  With earnings surprises well in the cards, healthcare ETFs are set to soar.